Department of Urology, Nanjing Drum Tower Hospital, Affiliated Hospital of Nanjing University Medical School, Nanjing, China.
Department of Urology, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, China.
BMC Cancer. 2024 Aug 14;24(1):1011. doi: 10.1186/s12885-024-12785-7.
Renal cell carcinoma (RCC) is a type of cancer that can develop at any point in adulthood, spanning the range of age-related changes that occur in the body. However, the specific molecular mechanisms underlying the connections between age and genetic mutations in RCC have not been extensively investigated.
Clinical and genetic data from patients diagnosed with RCC were collected from two prominent medical centers in China as well as the TCGA dataset. The patients were categorized into two groups based on their prognosticated age: young adults (YAs) and older adults (OAs). Univariate and multivariate analysis were employed to evaluate the relationships between age and genetic mutations. Furthermore, a mediation analysis was conducted to assess the association between age and overall survival, with genetic disparities serving as a mediator.
Our analysis revealed significant differences in clinical presentation between YAs and OAs with RCC, including histopathological types, histopathological tumor stage, and sarcomatoid differentiation. YAs were found to have lower mutation burden and significantly mutated genes (SMGs) of RCC. However, we did not observe any significant differences between the two groups in terms of 10 canonical oncogenic signaling pathways-related genes mutation, telomerase-related genes (TRGs) mutation, copy number changes, and genetic mutations associated with clinically actionable targeted drugs. Importantly, we demonstrate superior survival outcomes in YAs, and we confirmed the mediating effect of genetic disparities on these survival outcome differences between YAs and OAs.
Our findings reveal previously unrecognized associations between age and the molecular underpinnings of RCC. These associations may serve as valuable insights to guide precision diagnostics and treatments for RCC.
肾细胞癌(RCC)是一种可以在成年期的任何时候发生的癌症,涵盖了身体发生的与年龄相关的变化。然而,年龄与 RCC 中的遗传突变之间的具体分子机制尚未得到广泛研究。
从中国的两个著名医学中心以及 TCGA 数据集收集了诊断为 RCC 的患者的临床和遗传数据。根据预测年龄将患者分为两组:青年组(YAs)和老年组(OAs)。采用单变量和多变量分析评估年龄与遗传突变之间的关系。此外,还进行了中介分析,以评估年龄与总生存期之间的关系,其中遗传差异作为中介。
我们的分析显示,RCC 的 YAs 和 OAs 之间在临床表现方面存在显著差异,包括组织病理学类型、组织病理学肿瘤分期和肉瘤样分化。YAs 的突变负担和显著突变基因(SMGs)较低。然而,我们没有观察到两组在 10 个经典致癌信号通路相关基因突变、端粒酶相关基因(TRGs)突变、拷贝数变化和与临床可操作靶向药物相关的遗传突变方面存在显著差异。重要的是,我们证明了 YAs 的生存结果更好,并证实了遗传差异对 YAs 和 OAs 之间这些生存结果差异的中介作用。
我们的研究结果揭示了年龄与 RCC 的分子基础之间以前未被认识到的关联。这些关联可能为指导 RCC 的精准诊断和治疗提供有价值的见解。